The Research Institute \| Discovery Auditorium
September $7^{\text {th }}, 2018$

## Emerging strategies and novel therapeutics for patients with primary metastatic and relapsed bone and soft tissue sarcoma

| Program Agenda |  |
| :---: | :---: |
| 7:30-8 a.m. | Registration/ Breakfast |
| 8-8:30 a.m. | Introduction/Overview \| Bhuvana A. Setty, MD (NCH) |
| 8:30-9 a.m. | LSD1 in Ewing sarcoma: what a long strange trip it's been! Stephen A. Lessnick, MD, PhD (NCH) |
| 9-9:30 a.m. | Targeting osteosarcoma by manipulating the signals that osteosarcoma cells use to manipulate the lungs \| Ryan D. Roberts, MD, PhD (NCH) |
| 9:30-10 a.m. | Disrupting the paradigm of osteosarcoma therapy-novel players in a new order Nicola Mason, DVM, BVetMed (UPenn) |
| 10-10:15 a.m. | BREAK |
| 10:15-10:45 a.m. | Approaches to pediatric sarcoma diagnosis \\| Michael A. Arnold, MD, PhD (NCH) |
| 10:45-11:30 a.m. | Emerging strategies for the treatment of advanced rhabdomyosarcoma Abha Gupta, MD (Toronto) |
| 11:30 a.m. - 12:30 p.m. | Osteosarcoma: Learning from the past to move forward Katherine A. Janeway, MD (Boston) |
| 12:30-1:30 p.m. | LUNCH |
| 1:30-2 p.m. | Sarcoma biomarkers hiding in plain sight: Identifying targetable patient subsets James L. Chen, MD (OSUCCC) |
| $2-2: 30$ p.m. | Local control surgery in the metastatic patient Thomas Scharschmidt, MD (OSUCCC) |
| 2:30-3 p.m. | New developments in our understanding of desmoids Raphael Pollock, MD, PhD (OSUCCC) |


| $3-3: 30$ p.m. | Radiation treatment for pediatric sarcoma: Current management and future directions <br> Joshua Palmer, MD (OSUMC) |
| :---: | :---: |
| 3:30-3:45 p.m. | BREAK |
| 3:45-4:15 p.m. | Approaches to relapse Ewing sarcoma \| Lars Wagner, MD (Duke) |
| 4:15-4:45 p.m. | Emerging applications of hypofractionated radiotherapy for the treatment of metastatic and relapsed sarcomas Ralph Vatner, MD, PhD (UC Health) |
| 4:45-5:15 p.m. | Am I hot or not? The importance of immunologic temperature in sarcoma immunotherapies <br> Timothy P. Cripe, MD, $\mathrm{PhD}(\mathrm{NCH})$ |
| 5:15-5:30 p.m. | Closing Remarks/Discussion/Adjourn |

